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Abstract. 
 
This study has used biochemistry and real 
time confocal imaging of green ﬂuorescent protein 
(GFP)-tagged molecules in live cells to explore the dy-
namics of protein kinase B (PKB) regulation during B 
lymphocyte activation. The data show that triggering of 
the B cell antigen receptor (BCR) induces a transient 
membrane localization of PKB but a sustained activa-
tion of the enzyme; active PKB is found in the cytosol 
and nuclei of activated B cells. Hence, PKB has three 
potential sites of action in B lymphocytes; transiently 
after BCR triggering PKB can phosphorylate plasma 
membrane localized targets, whereas during the sus-
tained B cell response to antigen, PKB acts in the nu-
cleus and the cytosol. Membrane translocation of PKB 
and subsequent PKB activation are dependent on BCR 
activation of phosphatidylinositol 3-kinase (PI3K). 
Moreover, PI3K signals are both necessary and sufﬁ-
cient for sustained activation of PKB in B lymphocytes. 
However, under conditions of continuous PI3K activa-
tion or BCR triggering there is only transient recruit-
ment of PKB to the plasma membrane, indicating that 
there must be a molecular mechanism to dissociate 
PKB from sites of PI3K activity in B cells. The inhibi-
tory Fc receptor, the Fc
 
g
 
RIIB, mediates vital homeo-
static control of B cell function by recruiting an inositol 
5 phosphatase SHIP into the BCR complex. Herein we 
show that coligation of the BCR with the inhibitory
Fc
 
g
 
RIIB prevents membrane targeting of PKB. The 
Fc
 
g
 
RIIB can thus antagonize BCR signals for PKB lo-
calization and prevent BCR stimulation of PKB activity 
which demonstrates the mechanism for the inhibitory 
action of the Fc
 
g
 
RIIB on the BCR/PKB response.
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OREIGN
 
 antigen binding to the B cell antigen recep-
tor (BCR)
 
1
 
 triggers the activation of cytosolic ty-
rosine kinases including Syk and lyn and BTK
(Yamanashi et al., 1992; Desiderio and Siliciano, 1994;
Rawlings et al., 1996; DeFranco, 1997). These tyrosine
kinases then initiate a cascade of signaling pathways that
control B cell function during an immune response. The
BCR regulates the metabolism of inositol phospholipids
by two pathways: BCR stimulation of phospholipase C re-
sults in the hydrolysis of phosphatidylinositol (4,5) biphos-
phate [PI(4,5)P
 
2
 
] and the production of inositol 1,4,5-
triphosphate which initiates an increase in intracellular
calcium (Cambier and Jensen, 1994). PI(4,5)P
 
2
 
 breakdown
simultaneously produces diacylglycerol which activates
serine/threonine kinases of the protein kinase C family.
BCR triggering also stimulates the activity of phosphati-
dylinositol 3-kinase (PI3K) which phosphorylates PI(4,5)P
 
2
 
on the D-3 position of the inositol ring to produce
PI(3,4,5)P
 
3
 
 (Gold et al., 1992). D-3 phosphoinositides bind
to the plextrin homology (PH) domains of proteins and ei-
ther allosterically modify their activity or induce relocal-
ization of the protein to defined areas of the plasma mem-
brane where activation can occur (Rameh et al., 1997).
Genetic evidence for the importance of PI3K for B lympho-
cytes has been illustrated by the phenotype of mice lacking
expression of the p85
 
a
 
 regulatory adapter protein for
PI3K which show profound defects in B cell function (Fru-
man et al., 1999; Suzuki et al., 1999).
During B cell activation both positive and negative reg-
ulatory signaling cascades are vital for a balanced immune
response and immune homeostasis. One important nega-
tive feedback mechanism that operates in B cells is medi-
ated by the Fc
 
g
 
RIIb and the src homology 2 (SH2) do-
 
main containing inositol 5
 
9
 
 phosphatase (SHIP) (Takai
et al., 1996; Ono et al., 1997; Tridandapani et al., 1997;
Helgason et al., 1998; Okada et al., 1998; Sarao et al.,
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1998). Coligation of the BCR with the Fc
 
g
 
RIIB by anti-
gen–antibody complexes results in tyrosine phosphoryla-
tion of an immune cell tyrosine based inhibitory motif
(ITIM) in the Fc
 
g
 
RIIB (Burshtyn and Long, 1997). The
SH2 domain of SHIP can bind to the phosphorylated
ITIM, thereby recruiting this inositol 5
 
9
 
 phosphatase into
the BCR/Fc
 
g
 
RIIB complex. SHIP dephosphorylates PI
(3,4,5)P
 
3
 
 to produce PI(3,4)P
 
2
 
 and accordingly, coligation
of the BCR with Fc
 
g
 
RIIB diminishes BCR elevation of in-
tracellular PI(3,4,5)P
 
3
 
. PI3K controlled signaling pathways
are thus the proposed primary targets for Fc
 
g
 
RIIb inhibi-
tion (Hippen et al., 1997; Scharenberg et al., 1998; Scharen-
berg and Kinet, 1998).
Recent studies have identified two proteins regulated by
PI3K and SHIP in B cells: a tyrosine kinase Btk (Bolland
et al., 1998; Scharenberg et al., 1998) and a serine/threo-
nine kinase protein kinase B or Akt/PKB (Aman et al., 1998;
Jacob et al., 1999), the cellular homologue of the trans-
forming oncogene of the murine retrovirus Akt8 (Staal
and Hartley, 1988). PKB has been shown to play an impor-
tant role in maintenance of cell survival in fibroblasts and
epithelial cells (Zha et al., 1996; Kauffmann-Zeh et al.,
1997; Kulik et al., 1997). In T cells, PKB can stimulate the
activity of E2F transcription factors which are important
components of the mechanisms that control the mamma-
lian cell cycle (Brennan et al., 1997). PKB also phosphory-
lates and inactivates GSK3 (Cross et al., 1995), an enzyme
initially identified as a regulator of glycogen metabolism
but which also has broader functions: interactions between
GSK3 and 
 
b
 
-catenin (Rubinfeld et al., 1996) regulate ac-
tivity of the T cell factor–lymphoid enhancer factor (Tcf-
Lef). GSK3 can also control the nuclear export of nuclear
factor of activated T cells (NFAT), transcription factors in-
volved in cytokine gene induction (Beals et al., 1997).
In this report we have explored the dynamics of PKB
regulation by the BCR and the inhibitory Fc
 
g
 
RIIB in B
lymphocytes. We used green fluorescent protein (GFP;
Heim and Tsien, 1996; Rizzuto et al., 1996) to tag PKB and
time lapse confocal microscopy of live cells to reveal that
BCR regulation of Akt/PKB has the following sequence: a
rapid and transient recruitment of Akt/PKB to the plasma
membrane followed by a sustained activation of the en-
zyme. Analysis of the location of GFP-tagged PKB indi-
cated that active PKB is not normally maintained at the
plasma membrane but is found in the cytosol and nucleus.
We show that PI3K signals are both sufficient for mem-
brane recruitment of Akt/PKB and for sustained activa-
tion of the enzyme. BCR activation of PKB is subject to a
negative feedback control mechanism initiated by the
Fc
 
g
 
RIIB and mediated by SHIP (Aman et al., 1998). We
show that coligation of the BCR with the inhibitory
Fc
 
g
 
RIIB prevents membrane localization of PKB. These
data illustrate the importance of PI3K-mediated signals
in controlling the cellular localization of PKB and they
reveal the mechanism for the inhibitory action of the
Fc
 
g
 
RIIB on the BCR/PKB response.
 
Materials and Methods
 
Cells, Antibodies, Constructs, and Reagents
 
The BALB/c mouse B lymphoma line, A20, was cultured in RPMI 1640
 
supplemented with 10% fetal calf serum and 50 
 
m
 
M 
 
b
 
-mercaptoethanol.
Rabbit anti–mouse whole Ig antibody and F(ab
 
9
 
)
 
2
 
 fragment were obtained
from Zymed. The serine 473 phosphospecific PKB antibody was pur-
chased from New England Biolabs, the phosphospecific GSK3
 
a
 
 and the
pan anti-PKB
 
a
 
 were from Upstate Biotechnology, the pan anti-GSK3
 
a
 
antisera were from Santa Cruz Biotechnology. Rabbit antisera reactive
with the COOH-terminal residues 904–918 of PKD/PKC
 
m
 
 were generated
by standard protocols. Anti–sheep and anti–goat HRP-conjugated anti-
bodies were obtained from Chemicon, and anti–mouse HRP and anti–rab-
bit HRP were from Sigma Chemical Co. The rat CD2 monoclonal anti-
body OX34 and the 12CA5 monoclonal reactive with the Ha epitope tag
were purified from hybridoma supernatants by standard protocols. The
Fc
 
g
 
RIIB blocking antibody (FcBlock™) was purchased from PharMin-
gen. The PI3K inhibitor LY294002 was purchased from BIOMOL Re-
search Laboratories, the histone H2B was from Boehringer Mannheim,
the protein kinase inhibitor and ATP were from Sigma Chemical Co., and
the [
 
g
 
-
 
32
 
P]ATP was from Amersham.
A chimeric protein of the extracellular and transmembrane domain of
the rat CD2 molecule fused with the p110a catalytic subunit of PI3K
(rCD2p110) targets PI3K to the membrane and creates a constitutively ac-
tive enzyme that generates PI(3,4,5)P
 
3
 
 and PI(3,4)P
 
2
 
. The rCD2p110 con-
struct and a catalytically inactive form with a mutated ATP-binding site
(rCD2-p110R/P) were described previously (Reif et al., 1996, 1997). The
GFP-tagged PH domain of PKB and its non–lipid-binding R25C mutated
form were generated, respectively, from subcloning HindIII/BamH1 from
pCMV6 containing HA-tagged murine PKB
 
a
 
 PH domain (HA-AH) or
HA-R25C (Franke et al., 1995) into -C1 (Clontech), the BsrG1/Sal1 frag-
ment was then replaced by a linker of six glycine residues. Full length
PKB was COOH-terminally GFP-tagged using standard protocols. Oligo-
nucleotides introduced in pEGFP (Clontech) a sequence corresponding to
the COOH-terminal sequence of PKB from the BclI site to the end of the
protein at the NH
 
2
 
 terminus of GFP and a BglII site and a stop codon at
the COOH terminus of GFP. This resultant fragment was purified and li-
gated to pSG5 HA-PKB digested with BclI and BglII. All constructs were
verified by DNA sequencing. The GFP-PKB fusion protein undergoes ac-
tivation in response to BCR ligation (data not shown).
 
Cell Stimulation and Transfection
 
A20 cells were washed and resuspended at 2 
 
3
 
 10
 
7
 
/ml in RPMI 1640. The
cells were incubated at 37
 
8
 
C with either 10 
 
m
 
g/ml of anti–mouse F(ab
 
9
 
)
 
2
 
fragment or 15 
 
m
 
g/ml of intact Ig, for the indicated periods of time. Some
samples were preincubated with 5 
 
m
 
M of Ly294002 or 2.5 
 
m
 
g/ml anti-
Fc
 
g
 
RIIb for 30 min before stimulation. Cells were quickly pelleted at 4
 
8
 
C
and lysed in 50 mM Hepes, 10 mM NaF, 10 mM iodoacetamide, 75 mM
NaCl, 1% NP-40, 1 mM PMSF, 1 mM Na
 
2
 
VO
 
3
 
, and 1 
 
m
 
g/ml of each for leu-
peptin, pepstatin A, and chymotrypsin. Nuclear debris were eliminated by
20 min centrifugation at 14,000 rpm and the supernatant proteins precipi-
tated for 1 h at 
 
2
 
70
 
8
 
C in 1.5 vol acetone. Precipitates were pelleted by 20
min of centrifugation at 14,000 rpm, resuspended in Laemmli buffer,
boiled, and fractionated on 10% SDS-PAGE, with the exception of sam-
ples for GSK3 blotting, which were analyzed on 7.5% gels. Immunoblot-
ting was performed by standard protocols and revealed by chemilumines-
cence (ECL; Amersham). For transfection, 500 
 
m
 
l of cells was aliquoted
with DNA, electroporated at 310 V and 960 
 
m
 
F using a Bio-Rad gene
pulser. Thereafter cells were cultured for 12–14 h before stimulation, mi-
croscopic analysis, or lysis.
 
Immunoprecipitation and Kinase Assay
 
5 
 
3
 
 10
 
6
 
 cells transfected with HA-tagged PKB were stimulated as indi-
cated and lysed in 120 mM NaCl, 50 mM Hepes, 10 mM NaF, 1 mM
EDTA, 40 mM 
 
b
 
-glycerophosphate, 1% NP-40, 1 mM Na
 
2
 
VO
 
3
 
, and 1 
 
m
 
g/
ml of each for leupeptin, pepstatin A, and chymotrypsin. After elimination
of nuclear debris, the supernatant was cleared by addition of 1/25 vol of a
30% solution of Sepharose-coupled protein G. Supernatants were incu-
bated for 2 h with 10 
 
m
 
g/ml of the anti-HA antibody 12CA5, and another
45 min after addition of 1/10 vol of the Sepharose–protein G solution. Pel-
lets were washed once in lysis buffer, twice in 500 mM LiCl, 100 mM Tris,
pH 7.5, 1 mM EDTA, and once in assay buffer (50 mM Tris, pH 7.5, 10 mM
MgCl
 
2
 
, and 1 mM DTT). Dried samples were assayed by incubation for 30
min at room temperature with 2.5 
 
m
 
g H2B, 5 
 
m
 
M protein kinase inhibitor,
50 
 
m
 
M ATP, and 3 
 
m
 
Ci of [
 
g
 
-
 
32
 
P]ATP in a final volume of 15 
 
m
 
l. Boiled
samples in Laemmli buffer were fractionated by SDS-PAGE. The level of
H2B phosphorylation was analyzed by exposing the lower part of the gel 
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on a sensitive film, and the amount of PKB protein immunoprecipitated
was determined by Western blot analysis with a pan PKB antibody.
 
Nuclear Fractionation
 
After stimulation, cells were disrupted in 10 mM Hepes, 15 mM KCl, 2 mM
MgCl
 
2
 
, 0.1 mM EDTA, 10 mM NaF, 1 mM DTT, 1 mM PMSF, 1 mM
Na
 
2
 
VO
 
3
 
,
 
 
 
0.15% NP-40, and the nuclear fraction pelleted at 14,000 rpm for
1 min. Cytosolic extracts were removed and NaCl was added to obtain a
final concentration of 120 mM. These cytosolic extracts were then concen-
trated by acetone precipitation. The nuclear pellets were washed three
times with lysis buffer and then resuspended in 20 mM Hepes, 1.5 mM
MgCl
 
2
 
, 0.2 mM EDTA, 20% glycerol, 0.42 M NaCl, 10 mM NaF, 1 mM
DTT, 1 mM PMSF, 1 mM Na
 
2
 
VO
 
3
 
, 0.15% NP-40, and lysed for 30 min at
4
 
8
 
C. Debris was eliminated by 20 min of centrifugation at 14,000 rpm and
supernatants, corresponding to nuclear extracts, were acetone precipi-
tated.
 
Confocal Time Lapse Imaging
 
After transfection, cells were resuspended at 10
 
6
 
/ml in 35-mm glass bot-
tom dishes (MatTek Corp.). Before analysis dishes were gently rinsed
with warm Hanks’ medium without phenol red. Dishes were mounted in
the warm chamber of the confocal microscope (Zeiss Laser Scanning Mi-
croscope 5.10). Samples were excited at 488 nm by an argon laser and de-
tected with a 63 
 
3
 
 1.4 NA oil immersion objective. The first image was re-
corded just before stimulus addition directly into the dish, and then scans
were made automatically every 5 s by using Zeiss LSM software. Images
shown are representative of a minimum of five experiments. In Fig. 2,
anti-Fc
 
g
 
RIIB and LY294002 were added to the dishes in Hanks’ medium
30 min before microscopic analysis.
 
Results
 
The B lymphoma cell line A20 was either left unstimu-
lated or activated by cross-linking the BCR with F(ab
 
9
 
)
 
2
 
fragment of anti–mouse IgG. Active PKB is phosphory-
lated on two residues; threonine 308 and serine 473 by
PI3K-dependent protein kinases (Alessi et al., 1997; Alessi
and Cohen, 1998; Bellacosa et al., 1998; Stephens et al.,
1998). To monitor PKB activity in cells, total cell extracts
were prepared and fractionated by SDS-PAGE and pro-
cessed for Western blot analysis with a specific antisera
that recognizes active PKB molecules phosphorylated on
serine 473. The phospho-PKB antisera did not react with
PKB present in cell lysates from quiescent cells, whereas
in cells activated by cross-linking the BCR with F(ab
 
9
 
)
 
2
 
fragment of anti–mouse IgG there was a strong reactivity
of PKB with the phospho-PKB antisera (Fig. 1). The data
in Fig. 1 B show the in vitro catalytic activity of immune
complexes of PKB isolated from quiescent or BCR-trig-
gered cells, assayed using histone H2B as a substrate.
These data confirm that stimulation of B cells via the BCR
activates the catalytic activity of PKB. This result was con-
firmed also by analysis of the effects of BCR ligation on
the phosphorylation of GSK3, an endogenous substrate
for PKB (Cross et al., 1995). Phosphospecific antisera with
selectivity for GSK3 molecules phosphorylated on the
PKB substrate sequence do not recognize GSK3 proteins
isolated from quiescent B cells but are strongly reactive
with the GSK3 present in cell lysates prepared from BCR-
triggered cells (Fig. 1 C).
Cross-linking of the BCR with the Fc
 
g
 
RIIB inhibits
BCR signal transduction pathways by recruiting the inosi-
tol 5
 
9
 
 phosphatase SHIP into the BCR complex (Ono et al.,
1997; Tridandapani et al., 1997). The data in Fig. 1 A show
that B cell activation with intact IgG, which cross-links the
BCR with the Fc
 
g
 
RIIB, fails to stimulate PKB phosphory-
lation or PKB catalytic activity as judged by in vitro (Fig. 1
B) and in vivo (Fig. 1 C) assays of PKB function. In the
presence of an anti-Fc
 
g
 
RIIB antibody which blocks the in-
teraction of IgG with the Fc
 
g
 
RIIB receptor, intact IgG is
able to trigger the BCR without coligating inhibitory
Fc
 
g
 
RIIB into the BCR complex. The presence of the
blocking antibody to the Fc
 
g
 
RIIB then allows intact IgG
to ligate the BCR and stimulate PKB activity (Fig. 1).
 
PKB Localization in B Lymphocytes
 
Membrane localization of PKB is known to be essential
for the activation of the enzyme but there are conflicting
reports as to whether activated PKB is present in the nu-
cleus or maintained at the cell membrane (Andjelkovic et al.,
1997; Meier et al., 1997; Watton and Downward, 1999). To
examine the localization of PKB carefully in intact B cells
we expressed a GFP-tagged construct of wild-type PKB in
A20 cells and analyzed the cellular localization of this en-
zyme in quiescent and BCR-activated cells. Membrane
Figure 1. BCR and FcgRIIb regulation of PKB. The data show
PKB phosphorylation and activity in quiescent A20 cells or A20
cells stimulated for 10 min at 378C with the following stimuli: 10
mg/ml F(ab9)2 fragment of anti–mouse IgG which triggers the
BCR; 15 mg/ml of intact IgG of anti–mouse IgG which coligates
the BCR and the FcgRIIB complex; 15 mg/ml of intact Ig in cells
pretreated for 30 min with 2.5 mg/ml anti-FcgRIIB which pre-
vents FcgRIIB/BCR coligation and allows intact Ig to trigger the
BCR. The data in A show Western blots of total cell lysates per-
formed with serine 473 phosphospecific PKB antibody and pan
PKB antisera. The data in B show PKB kinase activity of immu-
noprecipitated Ha epitope–tagged PKB measured using histone
H2B as a substrate. H2B substrate phosphorylation was analyzed
by autoradiography. The data in C show Western blots of total
cell lysates performed with phosphospecific GSK3a and pan
GSK3a antisera. 
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targeting of PKB is mediated by interactions of the PH do-
main with either PI(3,4,5)P
 
3
 
 or PI(3,4)P
 
2
 
. Accordingly, we
examined also the cellular localization of a GFP-tagged
PKB-PH domain. Fig. 2 shows midsection confocal images
of A20 cells transiently transfected with GFP wild-type
PKB or the GFP-tagged PKB-PH domain. In unstim-
ulated A20 cells, GFP-PKB was uniformly distributed
throughout the cytosol of the cell and was also present in
the nucleus. The GFP-tagged PKB-PH domain of PKB
was similarly distributed. Western blot analysis of nuclear
extracts prepared from A20 cells revealed that endoge-
nous PKB was present in the nuclei of these lymphocytes
(Fig. 3).
 
BCR Ligation Induces a Transient Relocalization of 
PKB to the Plasma Membrane but a Sustained 
Activation of the Enzyme
 
A20 cells expressing GFP-PKB constructs were stimulated
with F(ab
 
9
 
)
 
2
 
 fragment of anti–mouse IgG and confocal im-
ages of a midsection of the cells were taken at 10-s inter-
vals after BCR ligation. This allows the effects of BCR
triggering on the cellular localization of PKB to be moni-
tored in live cells in real time. These images in Fig. 2 show
that triggering of the BCR induces a rapid membrane lo-
calization of both full length PKB and the PKB-PH do-
main. The membrane localization of both PKB constructs
was detected within 10 s of BCR ligation. Consistently, it
was seen that wild-type PKB recycles from the membrane
within 40–60 s of BCR triggering. In contrast, the translo-
cation of the PKB-PH domain to the membrane was sus-
tained (Fig. 2 A). The motility of the activated B cells
makes longer periods of confocal imaging live cells diffi-
cult but there was no indication of recycling of the PKB-
Figure 2. PKB localization in B cells. (A)
Confocal images of live A20 cells express-
ing GFP-tagged full length PKB (top) or
GFP-tagged PKB-PH domain (bottom).
Cells were stimulated with 10 mg/ml
F(ab9)2 fragment of anti–mouse IgG which
triggers the BCR and confocal images
taken at 10-s intervals. (B) A20 cells were
stimulated for the indicated times at 378C
with 10 mg/ml F(ab9)2 fragment of anti–
mouse IgG which triggers the BCR. The
data show Western blots of total cell ly-
sates performed with serine 473 phospho-
specific PKB antibody and pan PKB anti-
sera and phosphospecific GSK3a and pan
GSK3a antisera.
Figure 3. Cellular localiza-
tion of PKB in B cells. The
data show Western blot anal-
yses of nuclear and cytosolic
extracts of A20 cells per-
formed with serine 473 phos-
phospecific PKB antibody
and pan PKB antisera or
an antisera reactive with
the serine/threonine kinase
PKD/PKCm. Cells were ei-
ther quiescent or stimulated
for the indicated times with
10 mg/ml F(ab9)2 fragment of
anti–mouse IgG.Astoul et al. Akt/PKB Localization in B Cells 1515
PH domain away from the membrane over a period of
minutes. Thus, BCR-induced translocation of the PKB-PH
domain to the plasma membrane is stable compared with
the response of the full length GFP-tagged wild-type PKB.
A striking feature of the effect of the BCR on PKB
membrane localization is its speed and transience. Kinetic
analysis of the effect of the BCR on PKB activity reveals
that this is also a rapid response detectable within 30 s of
BCR triggering (data not shown). The data in Fig. 2 B
show that the effect of BCR ligation is to induce a stable
activation of PKB in a response that is maximal at 1 min
and sustained for at least 60 min (Fig. 2 B). It is also clear
that BCR induced phosphorylation of GSK3; an endoge-
nous substrate for PKB is a response that is maintained for
a period of 1–2 h (Fig. 2 B). In summary, analysis of PKB
cellular localization and activity shows that quiescent B
cells express PKB in the cytosol and the nucleus. BCR
triggering induces rapid membrane localization and acti-
vation of PKB. PKB targeting to the membrane in re-
sponse to BCR ligation is very transient and can be de-
tected within 10 s but is finished by 40–50 s. In contrast,
the stimulatory effects of the BCR on PKB activity are
sustained for at least 1 h. 1 min after BCR triggering there
is no discernible plasma membrane localized PKB, rather
the active PKB is present in either the cytosol or the nu-
cleus.
Active PKB Is Found in the Nucleus and Cytosol of 
BCR-triggered Cells
The question of the localization of active PKB is impor-
tant because it affords insight as to the potential site of ac-
tion of this kinase. To determine whether active PKB is
present in the nuclear or cytosolic compartment of B cells,
A20 cells were triggered via the BCR and cytosolic and
nuclear cell fractions were resolved by SDS-PAGE and
analyzed by Western blot with the phospho-PKB antibody
that recognizes active enzyme or with the pan PKB anti-
sera. These data (Fig. 3) show that endogenous PKB is
found in both the nucleus and cytosol of quiescent or acti-
vated B cells. In cells activated by cross-linking the BCR
with F(ab9)2 fragment of anti–mouse IgG there was a
strong reactivity of both cytosolic and nuclear PKB with
the phospho-PKB antisera. These results show that active
PKB is found in both the cytosol and nucleus of activated
B lymphocytes.
PI3 Kinase Signals Are Essential and Sufficient for 
Membrane Localization and Activation of PKB
in B Cells
PI3K signals are essential and sufficient for activation of
PKB in T lymphocytes (Reif et al., 1997). A comparison of
the data in Fig. 4, A and B, shows that the BCR-induced
transient membrane localization of GFP-PKB is abolished
by the PI3K inhibitor Ly294002. The data in Fig. 4 C show
that Ly294002 also prevents BCR activation of PKB.
Hence, the ability of the BCR to regulate the cell localiza-
tion and activity of PKB is dependent on PI3 kinase activ-
ity. To determine whether PI3K signals are sufficient for
membrane targeting and activation of PKB we examined
the effects of expression of constitutively active PI3 kinase
on PKB cellular localization and activity. The BCR stimu-
lates the activity of a PI3K complex that comprises a regu-
latory p85 and a catalytic p110 subunit. A chimeric protein
of the extracellular and transmembrane domain of the rat
CD2 molecule fused with the p110a catalytic subunit of
PI3K (rCD2p110) targets PI3K to the membrane and
creates a constitutively active enzyme that generates
PI(3,4,5)P3 and PI(3,4)P2 when expressed in cells. The
data in Fig. 5 show that expression of the constitutively ac-
tive PI3K, rCD2p110, induces a strong activation of PKB.
In these experiments A20 cells were transfected with
increasing concentrations of the rCD2p110 expression
vector resulting in increasing levels of expression of
rCD2p110. The effect of the active rCD2p110 constructs
on endogenous PKB activity was monitored using the
phospho-PKB antisera. The results (Fig. 5 A) show that
there was a dose-dependent stimulation of PKB activity by
the expressed active PI3K. This stimulatory effect of
rCD2p110 was dependent on the kinase activity of the
chimera since expression of a kinase inactive mutant,
rCD2p110 R/P, did not stimulate PKB activity. Moreover,
treatment of A20 cells with the PI3K inhibitor LY294002
abrogated PKB activity in cells expressing rCD2p110 (Fig.
5 B).
Confocal microscopy of cells cotransfected with rCD2-
p110 and GFP-tagged PKB constructs shows the localiza-
tion of PKB in cells expressing constitutively active PI3K.
These data reveal that membrane-localized PKB can be
detected in cells expressing active PI3 kinase (Fig. 6 A).
However, these cells also contain significant levels of cyto-
solic and nuclear GFP-PKB. In marked contrast, the total
cellular pool of the GFP-tagged PH domain of PKB is con-
stitutively present at the membrane of cells expressing ac-
tive PI3K (Fig. 6, A and B). In A20 cells stimulated via the
BCR (Fig. 2) we had noted that the wild-type PKB is only
transiently present at the cell membrane, whereas the
BCR-induced translocation of the isolated GFP-tagged
PKB-PH domain to the plasma membrane was sustained.
The results in Fig. 6 show clearly that in cells expressing a
constitutively active PI3K there is a stable and sustained
plasma membrane localization of the total cellular pool of
the PKB-PH domain but not a sustained membrane re-
cruitment of intact PKB.
The ability of active PI3K to sustain membrane localiza-
tion of the PKB-PH domain is dependent on the catalytic
activity of the enzyme. The application of the PI3K inhibi-
tor, Ly294002, to cells coexpressing rCD2p110 and the
GFP-tagged PKB-PH domain initiates a rapid relocation
of the PKB construct from the plasma membrane into the
cytosol and the nucleus. This striking response was com-
plete within 30 s of adding the PI3K inhibitor to the B cell
population (Fig. 6 B).
Coligation of the BCR with the FcgRIIb Prevents 
Membrane Localization of PKB
BCR activation of PKB is subject to a negative feedback
control mechanism initiated by the FcgRIIB and mediated
by SHIP (Fig. 1) (Aman et al., 1998). The stimulation of
PKB catalytic function requires membrane localization of
the kinase (Franke et al., 1997; Frech et al., 1997; Klippel
et al., 1997) plus its phosphorylation at two residues: thre-
onine 308 and serine 473 by PI3K-dependent protein ki-The Journal of Cell Biology, Volume 145, 1999 1516
nases (Alessi et al., 1997; Alessi and Cohen, 1998; Bella-
cosa et al., 1998; Stephens et al., 1998). The FcgRIIB/SHIP
complex will influence both the kinetics and magnitude of
PIP3 levels during B cell activation and could remove a
membrane targeting signal for PKB. However, SHIP de-
phosphorylates PI(3,4,5)P3 to form PI(3,4)P2 which is also
able to bind to the PH domain of PKB (Franke et al., 1997;
Frech et al., 1997). Thus, it is possible that PKB will still be
recruited to the plasma membrane when the BCR is coli-
gated with the FcgRIIB complex and that SHIP termi-
nates PKB-mediated responses by preventing the phos-
phorylation and activation of membrane-localized PKB.
For example, osmotic stress can prevent PKB activation
without preventing membrane localization of Akt/PKB
(Meier et al., 1998). To study the effects of BCR coligation
with the FcgRIIB on the cellular localization of PKB, A20
cells expressing the GFP-PKB constructs were stimulated
with either F(ab9)2 fragment of anti–mouse IgG or with in-
tact IgG. Confocal images of a midsection of the cells were
then taken at 5-s intervals after addition of the stimulus.
The results in Fig. 7 show that B cell activation with intact
IgG, which cross-links the BCR with the FcgRIIB, fails to
stimulate PKB membrane translocation. Fig. 7 shows con-
focal images of cells 15 s after BCR triggering but cells
were monitored for several minutes and no membrane lo-
calization of PKB could be seen in BCR/FcgRIIB coli-
gated cells at any time point. In the presence of an anti-
FcgRIIB antibody which blocks the interaction of IgG
with the FcgRIIB receptor, intact IgG is able to trigger the
BCR without coligating inhibitory FcgRIIB into the BCR
complex. The results show that presence of the blocking
antibody to the FcgRIIB then allows intact IgG to induce
plasma membrane localization of PKB.
Discussion
This study has used GFP-tagged PKB and time lapse con-
focal microscopy of live cells to follow the cellular localiza-
tion of PKB during antigen receptor activation of B lym-
phocytes. The data show that BCR regulation of PKB is a
dynamic process; there is an initial rapid and transient re-
cruitment of PKB to the plasma membrane followed by a
sustained activation of the enzyme. PKB localization to
the plasma membrane can be detected within 10 s of BCR
triggering but the response has finished after a further 40–
50 s. Stimulation of PKB catalytic activity is similarly rapid
and can be detected within 30 s of BCR triggering but the
activation of PKB is maintained for at least 1 h after BCR
Figure 4. BCR regulation of PKB membrane localization and activity is dependent on
PI3K. (A) Confocal images of live A20 cells expressing GFP-tagged full length PKB.
Cells were stimulated with 10 mg/ml F(ab9)2 fragment of anti–mouse IgG which triggers
the BCR and confocal images were taken at 10-s intervals. The data show confocal im-
ages of four cells at the zero and 15-s time points. (B) Confocal images of live A20 cells
expressing GFP-tagged full length PKB. Cells were pretreated for 30 min with 5 mM of
Ly294002, the PI3K inhibitor, and then stimulated with 10 mg/ml F(ab9)2 fragment of
anti–mouse IgG which triggers the BCR and confocal images taken at 5-s intervals. The
data show confocal images of two cells at the zero and 15-s time points. (C) A20 cells
were untreated or pretreated for 30 min with 5 mM of Ly294002, the PI3K inhibitor, and
then stimulated with 10 mg/ml F(ab9)2 fragment of anti–mouse IgG for 5 min. The data
show Western blot analyses of A20 cell lysates performed with serine 473 phosphospe-
cific PKB antibody and pan PKB antisera.Astoul et al. Akt/PKB Localization in B Cells 1517
triggering. PKB is distributed throughout the cytosol and
the nucleus of both quiescent and BCR-triggered B cells.
More importantly, in BCR-triggered B cells, phosphory-
lated active PKB is found in both the cytosol and nucleus.
The question of the localization of active PKB is impor-
tant because it affords insight as to the potential site of ac-
tion of this kinase during B cell activation. The present re-
sults show that PKB has three potential sites of action
during B cell activation. Transiently after BCR triggering,
PKB could function to phosphorylate plasma membrane
localized targets but during the sustained B cell response
PKB is acting in the nucleus and the cytosol. PKB is al-
ways present in the nucleus of the A20 cells but we have
no way to test whether the PKB that one sees in the nu-
Figure 5. PI3K signals are sufficient to activate PKB in
B cells. (A) A20 cells were transfected with either 5, 10,
or 20 mg of pEF rCD2p110 (active PI3K) or the equiva-
lent amounts of the control catalytically inactive pEF
rCD2p110R/P mutant. Cells were maintained in culture
for 14 h. The data show Western blot analysis of total
cell lysates from control cells or cells expressing the
PI3K mutant. The top shows Western blot experiments
with the rat CD2 antibody OX34 which monitors cellu-
lar levels of the rCD2 PI3K chimeras. The middle and
bottom show, respectively, Western blot analyses with
serine 473 phosphospecific PKB antibody and pan PKB
antisera. (B) A20 cells were transfected with 20 mg of
pEF rCD2p110 (active PI3K). Cells were maintained in
culture for 14 h. The data show Western blot analysis of total cell lysates from cells expressing rCD2p110 or after 3 h of incubation with
5 mM of Ly294002. The data show Western blot analyses with serine 473 phosphospecific PKB antibody (top) and pan PKB antisera
(bottom).
Figure 6. PKB localization in cells ex-
pressing constitutively active PI3K. (A)
Confocal images of live A20 cells
cotransfected with 20 mg of pEF
rCD2p110 (active PI3K) and either
GFP-tagged full length PKB (left) or
GFP-tagged PKB-PH domain (right).
After transfection, cells were main-
tained in culture for 14 h before confo-
cal imaging. (B) Confocal images of
live A20 cells cotransfected with 20
mg of pEF rCD2p110 (active PI3K)
and GFP-tagged PKB-PH domain. Af-
ter transfection, cells were maintained
in culture for 14 h before confocal im-
aging. Confocal images were taken at
10-s intervals after addition of 5 mM of
Ly294002 to inhibit PI3K activity.The Journal of Cell Biology, Volume 145, 1999 1518
cleus at time zero is the same PKB found in the nucleus
several minutes after BCR triggering. Mutations in the
PKB-PH domain that prevent PKB plasma membrane tar-
geting prevent PKB activation and we therefore assume
that the active PKB that we see in the nucleus has been ac-
tivated at the membrane. This would mean that there is a
dynamic turnover from the cytosol/nucleus to the mem-
brane and back to the cytosol and nucleus. The present re-
sults show that this cycle could be completed within 30–40 s.
The results in Fig. 2 show that PKB can move to the
plasma membrane within 10 s of activating the BCR. The
data in Fig. 6 show that the PKB-PH domain can leave the
membrane and enter the nucleus within 20–30 s. So PKB
could do a full cycle, cytosol/plasma membrane/nucleus,
within 30–40 s.
The FcgRIIb mediates vital homeostatic control of B
cell function by recruiting an inositol 5 phosphatase, SHIP,
into the BCR complex. The importance of the FcgRIIB/
SHIP complex for B cell homeostasis is illustrated by the
phenotype of mice lacking expression of either FcgRIIB
or SHIP which are prone to inflammatory disease and
show a higher sensitivity to anaphylaxis (Takai et al., 1996;
Helgason et al., 1998). FcgRIIB ligation with the BCR
prevents activation of PKB; this response was revealed by
quantitation of PKB activity in vitro but was confirmed
also by analysis of the effects of BCR and FcgRIIB coliga-
tion on the phosphorylation of GSK3, an endogenous sub-
strate for PKB. SHIP dephosphorylates PI(3,4,5)P3 to pro-
duce PI(3,4)P2 and is essential for the inhibitory action of
the FcgRIIB (Ono et al., 1997). The PH domain of PKB,
which mediates membrane targeting of the enzyme, is able
to bind the product of SHIP, PI(3,4)P2, in vitro. Neverthe-
less, the present data show that coligation of the BCR with
the inhibitory FcgRIIB prevents membrane targeting of
PKB. This was an intriguing result that reveals a mecha-
nism for the inhibitory action of the FcgRIIB on the BCR/
PKB response. It also suggests that binding of PI(3,4)P2 to
the PH domain of PKB in vivo is insufficient to target
PKB to the membrane. However, it should be emphasized
that accumulation of PI(3,4)P2 in BCR/FcgRIIb activated
B cells and has not been formally shown.
The PKB-PH domain was recruited stably to the mem-
brane in BCR-activated cells and also in cells expressing
constitutively active PI3K. The PKB-PH domain binds to
PIP3 and its translocation to the plasma membrane in B
cells was absolutely dependent on the continued presence
of D3 phosphoinositides: inhibition of the catalytic activity
of PI3K with LY294002 causes immediate loss of the PKB-
PH domain from the plasma membrane. It was particu-
larly striking that within 30–40 s of adding the PI3K in-
hibitor, the PKB-PH domain moves from the plasma
membrane into the cytosol and the nucleus of the B cell.
The stability of the membrane localization of the PKB-PH
domain was in marked contrast to the transient membrane
residence of intact wild-type PKB under conditions of con-
tinuous PI3K activation or BCR triggering. The loss of
wild-type active PKB from the plasma membrane within 1
min of BCR ligation is intriguing and cannot be explained
by limits in levels of cellular PIP3 because PIP3 levels are
elevated in A20 cells for at least 15 min after BCR ligation
(data not shown). Moreover, PKB is not maintained at the
membrane in cells expressing constitutively active PI3K
although the stability of the membrane targeting of the
PKB-PH domain confirms that there are sufficient levels
of D-3 phosphoinositides in activated B cells to tether
PKB to the membrane. Previous models have suggested
that PKB colocalizes with active PI3K to membrane sites
with elevated levels of D-3 phosphoinositides. The present
confocal imaging data comparing the localization of full
length PKB and the PKB-PH domain in B cells show that
the PKB-PH domain follows this model but the full length
PKB molecule does not. These studies thus reveal the ex-
istence of a molecular mechanism that must cause active
PKB to dissociate from the plasma membrane in B cells
despite the continued generation of PIP3. One possibility
is that phosphorylated and/or active full length PKB un-
Figure 7. The FcgRIIb prevents membrane
translocation of PKB. Confocal images of live
A20 cells expressing GFP-tagged full length
PKB. A20 cells stimulated at 378C with the
following stimuli: 10 mg/ml F(ab9)2 fragment
of anti–mouse IgG which triggers the BCR;
15 mg/ml of intact Ig which coligates the BCR
and the FcgRIIB complex; and 15 mg/ml of in-
tact Ig in cells pretreated for 30 min with 2.5
mg/ml anti-FcgRIIB which prevents FcgRIIB/
BCR coligation and allows intact Ig to trigger
the BCR. Confocal images were taken at 5-s
intervals; the data show confocal images
taken 15 s after A20 cell stimulation.Astoul et al. Akt/PKB Localization in B Cells 1519
dergoes a conformational change that prevents continued
lipid binding. Alternatively, PKB interactions with sub-
strate may relocalize the active kinase to the cytosol and
nucleus.
In summary, this study has used confocal imaging cou-
pled with more classical biochemical analyses to study the
dynamic PI3K-regulated processes that occur during B cell
activation. The BCR triggers a transient membrane local-
ization of PKB but a sustained activation of the enzyme;
active PKB is found in the cytosol and nuclei of BCR-stim-
ulated B cells. This result affords new information as to
the potential site of action of PKB during B cell activation.
Recent genetic studies have shown that PI3K is important
for B cell development and for B cell function in the pe-
ripheral lymphoid compartment. The present results show
that PI3K signals are both necessary and sufficient for sus-
tained activation of PKB in B lymphocytes which firmly
positions Akt/PKB in PI3K-mediated signaling pathways
in B lymphocytes. There has been much recent informa-
tion about the effects of antigen receptors on membrane-
localized signaling pathways in lymphocytes; the signifi-
cance of the present report is that the PI3K/PKB pathway
couples signaling events triggered at the lymphocyte mem-
brane to the cell nucleus.
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